Table 1.
Patient baseline characteristics.
Table 2.
(a) Mean Z-scores for the time-weighted averages of galactomannan and beta-D-glucan composite values, and (b) time-weighted averages for beta-D-glucan values, galactomannan values, and galactomannan optical density index, in responders vs non-responders at week 6 and week 12.
Fig 1.
Kaplan-Meier survival curves among: (A) patients with hematologic malignancies and stem cell transplant recipients compared to patients with other underlying diseases, and (B) patients with positive vs negative baseline galactomannan enzyme immunoassay optical density index.
In Fig 1A, 0 (solid line) represents “other populations” and 1 (dashed line) represents patients with “HSCT/BMT patients”. In Fig 1B, 0 (solid line) represents patients with negative GMI at baseline, and 1 (dashed line) represents patients with positive GMI at baseline.
Table 3.
(a) Mean Z-scores for the time-weighted averages of galactomannan and beta-D-glucan composite values, and (b) time-weighted averages for beta-D-glucan values, galactomannan values, and galactomannan optical density index, by patient survival (alive vs dead) at week 6 and week 12.
Table 4.
Association of galactomannan assay optical density index (GMI) as a dichotomous variable (positive [GMI ≥ 0.5] vs negative) between baseline and week 2 of treatment with clinical response and survival at 6 and 12 weeks.